Filing Flows › Karyopharm Therapeutics (KPTI) › R&D spending
Karyopharm Therapeutics (KPTI) R&D spending by quarter
Karyopharm Therapeutics' R&D spending was $29.0M in Q2 2026 (second quarter 2026), -14% from Q1 2026. Over the last 7 quarters it ranged from $27.7M (Q4 2025) to $34.6M (Q1 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $29.0M | -14% | -12% |
| Q1 2026 | $33.8M | +22% | -2% |
| Q4 2025 | $27.7M | -9% | -17% |
| Q3 2025 | $30.5M | -7% | — |
| Q2 2025 | $32.8M | -5% | — |
| Q1 2025 | $34.6M | +4% | — |
| Q4 2024 | $33.3M | — | — |
Q2 2026 at a glance
Karyopharm Therapeutics, Q2 2026: revenue $33.4M (-12% year over year), operating margin -67.4%, net loss $67.0M, operating cash flow −$24.9M. The chart follows the revenue to costs, profit and cash.
Questions
What is Karyopharm Therapeutics' R&D spending?
Karyopharm Therapeutics' R&D spending was $29.0M in Q2 2026 (second quarter 2026), -14% from Q1 2026.
How has Karyopharm Therapeutics' R&D spending changed?
Over the last 7 quarters it ranged from $27.7M (Q4 2025) to $34.6M (Q1 2025).
Q2 2026 results → · How Karyopharm Therapeutics makes money →